Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabri…

Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by ...